xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

423

ICAR SINONASAL TUMORS

1231. Sparber-Sauer M, Ferrari A, Kosztyla D, et al. Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sar coma in children, adolescents, and young adults. Pediatr Blood Cancer . 2022;69(9):e29691. https://doi.org/10.1002/pbc.29691 1232. Crist W, Gehan EA, Ragab AH, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol . 1995;13(3):610-630. https://doi.org/10.1200/JCO.1995.13.3.610 1233. Arndt CAS, Stoner JA, Hawkins DS, et al. Vincristine, acti nomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vin cristine, topotecan, and cyclophosphamide for intermediate risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol . 2009;27(31):5182-5188. https://doi.org/10. 1200/JCO.2009.22.3768 1234. Oberlin O, Rey A, Sanchez de Toledo J, et al. Random ized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhab domyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the Inter national Society of Pediatric Oncology MMT95 study. J Clin Oncol . 2012;30(20):2457-2465. https://doi.org/10.1200/ JCO.2011.40.3287 1235. Thompson CF, Kim BJ, Lai C, et al. Sinonasal rhabdomyosar coma: prognostic factors and treatment outcomes. Int Forum Allergy Rhinol . 2013;3(8):678-683. https://doi.org/10.1002/alr. 21157 1236. Sercarz JA, Mark RJ, Tran L, Storper I, Calcaterra TC. Sar comas of the nasal cavity and paranasal sinuses. Ann Otol Rhinol Laryngol . 1994;103(9):699-704. https://doi.org/10.1177/ 000348949410300907 1237. Li W, Lu H, Wang D. Therapeutic outcome and prognostic factors in sinonasal rhabdomyosarcoma: a single-institution case series. J Cancer Res Clin Oncol . 2019;145(11):2793-2802. https://doi.org/10.1007/s00432-019-03009-8 1238. Kana LA, Smith JD, Bellile EL, Chugh R, McKean EL. Surgi cal management of rhabdomyosarcoma of the nasal cavity and paranasal sinuses: analysis of operative indications, settings, and outcomes. J Neurol Surg B Skull Base . 2022;83(4):350-358. https://doi.org/10.1055/s-0041-1736590 1239. Hahn E, Barot S, O’Sullivan B, et al. Adult head and neck rhabdomyosarcoma: management, outcomes, and the effect of intensity modulated radiation therapy on locoregional con trol. Adv Radiat Oncol . 2022;7(6):101055. https://doi.org/10. 1016/j.adro.2022.101055 1240. Ding J, Wang C, Xiang J, et al. Treatment outcomes and prog nostic factors of adult sinonasal sarcomas: a single-institution case series. Med Sci Monit . 2018;24:6113-6118. https://doi.org/ 10.12659/MSM.909116 1241. Stepan K, Konuthula N, Khan M, et al. Outcomes in adult sinonasal rhabdomyosarcoma. Otolaryngol Head Neck Surg . 2017;157(1):135-141. https://doi.org/10.1177/0194599817696287 1242. Szablewski V, Neuville A, Terrier P, et al. Adult sinonasal soft tissue sarcoma: analysis of 48 cases from the French Sarcoma Group database. Laryngoscope . 2015;125(3):615-623. https://doi.org/10.1002/lary.24910 1243. Flamant F, Rodary C, Rey A, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the Inter-

1218. Wolfish EB, Nelson BL, Thompson LDR. Sinonasal tract mucoepidermoid carcinoma: a clinicopathologic and immunophenotypic study of 19 cases combined with a comprehensive review of the literature. Head Neck Pathol . 2012;6(2):191-207. https://doi.org/10.1007/s12105-011-0320-9 1219. da Cruz Perez DE, Pires FR, Lopes MA, de Almeida OP, Kowalski LP. Adenoid cystic carcinoma and mucoepider moid carcinoma of the maxillary sinus: report of a 44-year experience of 25 cases from a single institution. J Oral Maxillo fac Surg . 2006;64(11):1592-1597. https://doi.org/10.1016/j.joms. 2005.11.088 1220. Biron VL, Lentsch EJ, Gerry DR, Bewley AF. Case-control analysis of survival outcomes in sinonasal acinic cell carci noma. Int Forum Allergy Rhinol . 2014;4(6):507-511. https://doi. org/10.1002/alr.21301 1221. Hawkins DS, Spunt SL, Skapek SX, COG Soft Tissue Sar coma Committee. Children’s Oncology Group’s 2013 blueprint for research: soft tissue sarcomas. Pediatr Blood Cancer . 2013;60(6):1001-1008. https://doi.org/10.1002/pbc.24435 1222. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhab domyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol . 2009;27(20):3391-3397. https://doi.org/10.1200/JCO.2008.19.7483 1223. Leiner J, Le Loarer F. The current landscape of rhabdomyosar comas: an update. Virchows Arch . 2020;476(1):97-108. https:// doi.org/10.1007/s00428-019-02676-9 1224. Raney RB, Meza J, Anderson JR, et al. Treatment of children and adolescents with localized parameningeal sarcoma: expe rience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol . 2002;38(1):22-32. https://doi.org/10.1002/mpo.1259 1225. Merks JHM, De Salvo GL, Bergeron C, et al. Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European coopera tive groups. AnnOncol . 2014;25(1):231-236. https://doi.org/10. 1093/annonc/mdt426 1226. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhab domyosarcoma study-IV: results for patients with non metastatic disease. J Clin Oncol . 2001;19(12):3091-3102. https:// doi.org/10.1200/JCO.2001.19.12.3091 1227. Maurer HM, Gehan EA, Beltangady M, et al. The intergroup rhabdomyosarcoma study-II. Cancer . 1993;71(5):1904-1922. https://doi.org/10.1002/1097-0142(19930301)71:5 ⟨ 1904::aid cncr2820710530 ⟩ 3.0.co;2-x 1228. Raney RB, Maurer HM, Anderson JR, et al. The intergroup rhabdomyosarcoma study group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma . 2001;5(1):9-15. https://doi.org/10.1080/13577140120048890 1229. Siddiqui SH, Siddiqui E, Bavier RD, et al. Clinicopatho logic traits and prognostic factors associated with pediatric sinonasal rhabdomyosarcoma. Int Forum Allergy Rhinol . 2019;9(4):363-369. https://doi.org/10.1002/alr.22267 1230. Fyrmpas G, Wurm J, Athanassiadou F, et al. Man agement of paediatric sinonasal rhabdomyosarcoma. J Laryngol Otol . 2009;123(9):990-996. https://doi.org/10.1017/ S0022215109005337